Cipla acquires Wellthy stake to bring digital therapeutics to India

19 February 2019

Indian drugmaker Cipla (BSE: 500087) is to acquire an 11.7% stake in digital therapeutics company Wellthy Therapeutics.

Cipla subsidiary Goldencross Pharma will pay 105 million rupees ($1.5 million) and the companies will start work on a partnership to offer digital therapeutics for diabetes and cardiovascular diseases.

"Companion digital therapeutics are redefining the treatment of chronic conditions"Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with these diseases via doctors’ clinics or co-packaging on select Cipla brands.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK